If this is a medical emergency, call 10177 (ambulance) or go to your nearest emergency room immediately.
CANSA Patient Support: 0800 22 6622 (toll-free)
This article covers your medical aid rights during a lymphoma-related emergency or coverage crisis. Read it once the immediate medical situation is stable.
What Your Medical Aid Must Cover in an Emergency
Lymphoma is a PMB condition. In any emergency related to lymphoma or its treatment, your scheme must fund emergency care at any registered hospital regardless of network status, prior authorisation, or oncology sub-limit position.
Common lymphoma emergencies and PMB obligations:
| Emergency | PMB Status | Notes |
|---|---|---|
| Febrile neutropenia (post-chemotherapy) | Yes — PMB | Requires urgent hospitalisation; G-CSF (filgrastim) support |
| Superior vena cava (SVC) syndrome (mediastinal mass) | Yes — emergency PMB | Urgent radiation or systemic therapy |
| Spinal cord compression (lymphoma mass or bone involvement) | Yes — emergency PMB | Urgent radiation or surgical decompression |
| Tumour lysis syndrome (TLS) | Yes — PMB | ICU-level monitoring required; occurs after chemotherapy in high-burden disease |
| Airway compromise (large mediastinal lymphoma) | Yes — emergency PMB | May require urgent radiation before chemotherapy |
| Haemorrhage or thrombocytopenia requiring transfusion | Yes — PMB | Blood products funded as PMB |
| Sepsis (immune-compromised patient) | Yes — emergency PMB | |
| Pulmonary embolism (cancer-associated) | Yes — PMB (separate DVT/PE DTP) |
Tumour lysis syndrome (TLS): This is a specific lymphoma emergency that can occur in the first 24–72 hours after starting chemotherapy for high-burden disease (especially Burkitt lymphoma and aggressive DLBCL). It requires ICU-level monitoring, IV fluids, allopurinol or rasburicase, and electrolyte management. Your scheme must fund TLS management as part of the PMB chemotherapy benefit.
Hospital Admission: What to Know
In a genuine emergency: Present at the nearest appropriate facility. Schemes must fund emergency stabilisation without pre-authorisation. Have someone notify your scheme's 24-hour emergency line within 24–48 hours.
For chemotherapy admissions (planned): Pre-authorisation is required per cycle or per course. Ask your haematologist's rooms to confirm the authorisation is in place before each treatment date.
Urgent chemotherapy starts: For aggressive lymphomas (DLBCL, Burkitt), treatment sometimes needs to start within 24–48 hours of diagnosis. Notify your case manager explicitly that treatment is clinically urgent — most schemes have an expedited pre-authorisation pathway for oncological emergencies. Follow up by phone, not just by email.
If Your Scheme Declines or You Cannot Pay
If rituximab or another treatment is declined:
- Request written reasons for the decline.
- Have your haematologist submit a clinical motivation citing published evidence (SANHUG guidelines, international guidelines).
- Submit a formal appeal. Request a peer-to-peer review between your haematologist and the scheme's medical advisor.
- If the appeal is declined: CMS complaint (0861 123 267 | www.medicalschemes.co.za). The CMS adjudicates PMB disputes and rulings are binding.
If your oncology sub-limit has been exhausted:
Standard chemotherapy (CHOP, ABVD) as the PMB minimum treatment cannot be stopped because the sub-limit was reached. The sub-limit governs non-PMB oncology expenditure. If your scheme attempts to stop funding active first-line PMB treatment because of the sub-limit, put this challenge in writing and escalate to the CMS immediately.
Outstanding hospital accounts:
- Request itemised accounts and check for errors.
- For specialist shortfalls (haematologist, anaesthesiologist), contact the practice manager to negotiate a payment arrangement on the gap component.
After the Crisis: Next Steps
- Confirm your PMB registration remains active and your case manager is still assigned.
- Request a benefit statement showing sub-limit usage — confirm emergency treatment was classified as PMB, not deducted from the sub-limit.
- Upcoming benefit year: Lymphoma treatment frequently crosses the January year-end. Plan with your case manager in November–December to ensure seamless authorisation into the new benefit year.
- Stem cell transplant planning: If relapse occurs and ASCT is being discussed, initiate the authorisation process immediately — transplant authorisation can take 2–4 weeks and should not be left to the last moment.
Resources and Helplines
Emergency services: 10177 (ambulance) | 10111 (police) CANSA: 0800 22 6622 (toll-free, weekdays) Lymphoma Foundation SA: lymphomafoundation.co.za Council for Medical Schemes: 0861 123 267 | www.medicalschemes.co.za Talk to Eldon →